Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis

被引：0
|
作者：
Hauser, Stephen L. [1 ]
Kappos, Ludwig [2 ]
Montalban, Xavier [3 ]
Chognot, Cathy [4 ]
Jessop, Nikki [4 ]
Pradhan, Ashish [5 ]
Prajapati, Kalpesh [6 ]
Wolinsky, Jerry S. [7 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Univ Basel, Univ Hosp Basel, Basel, Switzerland
[3] Vall dHebron Univ Hosp, Barcelona, Spain
[4] F Hoffmann La Roche Ltd, Basel, Switzerland
[5] Genentech Inc, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA
[6] QVIA Solut Inc, London, England
[7] Univ Texas Hlth Sci Ctr Houston, UTHlth, McGovern Med Sch, Houston, TX 77030 USA
来源：
NEUROLOGY | 2021年 / 96卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1812
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
    Turner, Benjamin
    Cree, Bruce A. C.
    Kappos, Ludwig
    Montalban, Xavier
    Papeix, Caroline
    Wolinsky, Jerry S.
    Buffels, Regine
    Fiore, Damian
    Garren, Hideki
    Han, Jian
    Hauser, Stephen L.
    [J]. JOURNAL OF NEUROLOGY, 2019, 266 (05) : 1182 - 1193
  • [42] Real world experience with ocrelizumab in patients with primary progressive multiple sclerosis
    Lopez Ruiz, R.
    Dotor Garcia-Soto, J.
    Hiraldo, J. D. G.
    Ruiz-Pena, J. L.
    Paramo Camino, M. D.
    Ruiz De Arcos, M.
    Navarro Mascarell, G.
    Eichau Madueno, S.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 301 - 302
  • [43] SOCIOECONOMIC VALUE OF OCRELIZUMAB IN THE TREATMENT OF PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
    Di Maio, D.
    Liu, C.
    Marcelli, G.
    Alvarez, Sanchez J.
    Overell, J.
    [J]. VALUE IN HEALTH, 2020, 23 : S632 - S633
  • [44] Effectiveness and safety of ocrelizumab in patients with multiple sclerosis
    Madrid-Paredes, A.
    Alvarez-Sanchez, R.
    Nieto-Gomez, P.
    Portillo-Haro, S.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2020, 42 (01) : 287 - 287
  • [45] Ocrelizumab: A New B-cell Therapy for Relapsing Remitting and Primary Progressive Multiple Sclerosis
    Stahnke, Amanda M.
    Holt, Kathryn M.
    [J]. ANNALS OF PHARMACOTHERAPY, 2018, 52 (05) : 473 - 483
  • [46] Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis
    Bar-or, A.
    Thanei, G. -A.
    Harp, C.
    Cross, A.
    Hauser, S.
    Jia, X.
    Kuhle, J.
    Leppert, D.
    Model, F.
    Fiore, D.
    Koendgen, H.
    Hendricks, R.
    Fischer, S.
    Manfrini, M.
    Herman, A.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 197 - 197
  • [47] Ocrelizumab in Highly Disabled Progressive Multiple Sclerosis Patients
    Howard, D.
    Healy, B. C.
    Houtchens, M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 201 - 201
  • [48] Evaluation of Ocrelizumab in Older Progressive Multiple Sclerosis Patients
    Epstein, S.
    Fong, K. T.
    Levine, L.
    De Jager, P. L.
    Riley, C. S.
    Vargas, W. S.
    Farber, R.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (1_SUPPL) : 50 - 51
  • [49] Ocrelizumab in highly disabled progressive multiple sclerosis patients
    Houtchens, Maria
    Howard, Danielle
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 82
  • [50] Evaluation of ocrelizumab in older progressive multiple sclerosis patients
    Epstein, Samantha
    Fong, Kathryn T.
    De Jager, Philip L.
    Levine, Libby
    Riley, Claire
    Wesley, Sarah
    Vargas, Wendy S.
    Farber, Rebecca
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 55
12345